Martinsried, Germany, November 6, 2006. KINAXO Biotechnologies GmbH announced today that it has entered into a services and collaboration agreement with UCB S.A. of Brussels, Belgium (UCB). Under the agreement, KINAXO will employ the KinaTorTM technology to perform selectivity analyses for several of UCB's small molecule lead compounds in cells and tissue samples. "We are very pleased with this collaboration to support UCB's lead optimisation programmes," said Dr. Andreas Jenne, CEO of KINAXO. "We will apply our chemical proteomics technology KinaTorTM to assist UCB in the development of drugs with well-characterized inhibition profiles."
About KinaTorTM The KinaTorTM technology uses immobilized small molecule inhibitors to detect their protein binding partners in biological samples. Small molecule-protein interactions are identified by a combination of sophisticated affinity-based separation procedures and sensitive mass spectrometry. The KinaTorTM provides tailor-made solutions for various applications, such as the identification of previously unknown disease-relevant targets as well as off-target related toxicities.
About KINAXO KINAXO Biotechnologies GmbH is a spin-off from the Max Planck Institute of Biochemistry in Martinsried. KINAXO offers a comprehensive chemical-proteomics technology - known as KinaTorTM - to identify and characterize the interaction of small molecule inhibitors with their protein targets in the physiological context of a cell. Tailored to protein kinases, the KinaTorTM technology represents a highly efficient approach to developing selective kinase inhibitors for targeted therapies.
About UCB UCB (www.ucb-group.com) is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing over 8,300 people in over 40 countries, UCB achieved revenue of 2.3 billion Euro in 2005. UCB is listed on the Euronext Brussels Exchange and its worldwide headquarters are located in Brussels, Belgium.
Contact
Dr. Andreas Jenne, CEO KINAXO Biotechnologies GmbH Am Klopferspitz 19a 82152 Martinsried, Germany www.kinaxo.com
Phone: +49 89 700763 831 Email: [email protected]
